NASDAQ:FDMT 4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis $8.32 -0.08 (-0.95%) Closing price 04:00 PM EasternExtended Trading$8.32 -0.01 (-0.06%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About 4D Molecular Therapeutics Stock (NASDAQ:FDMT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get FDMT alerts:Sign Up Key Stats Today's Range$8.11▼$8.4550-Day Range$4.41▼$8.7352-Week Range$2.23▼$9.52Volume574,133 shsAverage Volume655,614 shsMarket Capitalization$388.54 millionP/E RatioN/ADividend YieldN/APrice Target$30.40Consensus RatingModerate Buy Company Overview 4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches. 4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas. Notable programs target inherited retinal disorders—such as X-linked retinitis pigmentosa and achromatopsia—as well as investigational candidates for neuromuscular and metabolic diseases. By tailoring capsid design to specific tissues, the company seeks to optimize safety and efficacy in patient populations with high unmet medical need. To support its research and development efforts, 4D Molecular Therapeutics engages in collaborations with academic institutions and industry partners in the United States and Europe. The company completed its initial public offering in October 2017, trading on the NASDAQ under the symbol FDMT, and has used the proceeds to advance its clinical and preclinical programs. The company is led by President and Chief Executive Officer John J. Falcon, whose leadership team comprises experienced professionals in gene therapy development, regulatory affairs and commercial strategy. Under Falcon’s guidance, 4D Molecular Therapeutics continues to advance its innovative platform with the goal of delivering transformative treatments to patients suffering from rare genetic disorders.AI Generated. May Contain Errors. Read More 4D Molecular Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreFDMT MarketRank™: 4D Molecular Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 560th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus Rating4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 8 buy ratings, 1 hold rating, and 2 sell ratings.Upside Potential4D Molecular Therapeutics has a consensus price target of $30.40, representing about 265.4% upside from its current price of $8.32.Amount of Analyst Coverage4D Molecular Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about 4D Molecular Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($2.84) to ($3.34) per share.Price to Book Value per Share Ratio4D Molecular Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about 4D Molecular Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.04% of the outstanding shares of 4D Molecular Therapeutics have been sold short.Short Interest Ratio / Days to Cover4D Molecular Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in 4D Molecular Therapeutics has recently increased by 9.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield4D Molecular Therapeutics does not currently pay a dividend.Dividend Growth4D Molecular Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.04% of the outstanding shares of 4D Molecular Therapeutics have been sold short.Short Interest Ratio / Days to Cover4D Molecular Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in 4D Molecular Therapeutics has recently increased by 9.07%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment1.39 News Sentiment4D Molecular Therapeutics has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for 4D Molecular Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for FDMT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, 4D Molecular Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,256.00 in company stock.Percentage Held by InsidersOnly 9.60% of the stock of 4D Molecular Therapeutics is held by insiders.Percentage Held by Institutions99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 4D Molecular Therapeutics' insider trading history. Receive FDMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FDMT Stock News HeadlinesInsider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells 2,407 Shares of StockSeptember 30, 2025 | insidertrades.comIs 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth?October 3, 2025 | finance.yahoo.comNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.October 7 at 2:00 AM | Brownstone Research (Ad)4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise InvestorsSeptember 30, 2025 | seekingalpha.com4DMT Announces New Employment Inducement GrantsSeptember 12, 2025 | globenewswire.com4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comJim Cramer on 4D Molecular Therapeutics: “This is a Pure Spec”September 5, 2025 | insidermonkey.com4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA ReadinessSeptember 2, 2025 | globenewswire.comSee More Headlines FDMT Stock Analysis - Frequently Asked Questions How have FDMT shares performed this year? 4D Molecular Therapeutics' stock was trading at $5.57 at the beginning of the year. Since then, FDMT stock has increased by 49.4% and is now trading at $8.32. How were 4D Molecular Therapeutics' earnings last quarter? 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) issued its earnings results on Monday, August, 11th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.88) by $0.10. The business earned $0.01 million during the quarter, compared to analyst estimates of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative trailing twelve-month return on equity of 40.15%. When did 4D Molecular Therapeutics IPO? 4D Molecular Therapeutics (FDMT) raised $101 million in an initial public offering on Friday, December 11th 2020. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager. Who are 4D Molecular Therapeutics' major shareholders? Top institutional shareholders of 4D Molecular Therapeutics include Assenagon Asset Management S.A. (1.42%). Insiders that own company stock include Global Investors Lp Viking, David Kirn, Scott Bizily and Robert Young Kim. View institutional ownership trends. How do I buy shares of 4D Molecular Therapeutics? Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 4D Molecular Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that 4D Molecular Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings8/11/2025Today10/07/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FDMT CIK1650648 Webwww.4dmoleculartherapeutics.com Phone510-505-2680FaxN/AEmployees120Year Founded2013Price Target and Rating Average Price Target for 4D Molecular Therapeutics$30.40 High Price Target$44.00 Low Price Target$6.00 Potential Upside/Downside+265.4%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$160.87 million Net Margins-594,375.81% Pretax Margin-594,375.75% Return on Equity-40.15% Return on Assets-36.43% Debt Debt-to-Equity RatioN/A Current Ratio8.75 Quick Ratio8.75 Sales & Book Value Annual Sales$40 thousand Price / Sales9,713.60 Cash FlowN/A Price / Cash FlowN/A Book Value$11.05 per share Price / Book0.75Miscellaneous Outstanding Shares46,700,000Free Float42,219,000Market Cap$388.54 million OptionableOptionable Beta2.93 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:FDMT) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.